Translational Development Acquisition Corp. - Units (TDACU)

On our desk, we are closely tracking the valuation metrics for TDAC. With CirclFi's Quality Score resting at 4.7 out of 10 and four out of five models signaling overvaluation at current prices around $10.83, the broader market consensus leans decidedly bearish despite the ongoing special-purpose acquisition activity.

Watching the 50-day MA crossover, our quant group noted that the 10-day moving average crossed bullishly above the 50-day moving average on July 31, 2026. Historically, past instances of this technical setup have shown a tendency for the asset to drift higher over the ensuing month.

As a bio-analyst looking at the underlying asset pipeline, the core fundamental catalyst remains the definitive merger agreement executed with ProLogium to take the solid-state battery enterprise public via a two-step merger structure, backed by a secured $50M subscription.

In our risk management review, we noted that separate trading of Class A ordinary shares and warrants from the initial public offering units commenced back in February 2025, providing distinct liquidity pools for equity and warrant holders as the ProLogium transaction progresses.

Reviewing the latest 10-Q filing for Q2 2026, net income dropped to $946,982 down from $1,623,342 in Q2 2025, bringing diluted EPS down to $0.04 from $0.07. For the first six months of 2026, net income fell 26.6% year-over-year to $2,279,779, pointing to compressed operational margins.